Immune Landscape in PD-L1-positive and TROP2-positive Triple-Negative Breast Cancer

被引：0
|
作者：
Gyorffy, Balazs
Santarpia, Libero
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO2-03-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO2-03-07
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Spatial Profile of Tumor Microenvironment in PD-L1-Negative and PD-L1-Positive Triple-Negative Breast Cancer
    Tashireva, Liubov A.
    Kalinchuk, Anna Yu.
    Gerashchenko, Tatiana S.
    Menyailo, Maksim
    Khozyainova, Anna
    Denisov, Evgeniy V.
    Perelmuter, Vladimir M.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (02)
  • [2] Prognostic significance of PD-L1-positive cancer-associated fibroblasts in patients with triple-negative breast cancer
    Yoshikawa, Katsuhiro
    Ishida, Mitsuaki
    Yanai, Hirotsugu
    Tsuta, Koji
    Sekimoto, Mitsugu
    Sugie, Tomoharu
    BMC CANCER, 2021, 21 (01)
  • [3] Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer
    Mavratzas, Athanasios
    Seitz, Julia
    Smetanay, Katharina
    Schneeweiss, Andreas
    Jaeger, Dirk
    Fremd, Carlo
    FUTURE ONCOLOGY, 2020, 16 (03) : 4439 - 4453
  • [4] Prognostic significance of PD-L1-positive cancer-associated fibroblasts in patients with triple-negative breast cancer
    Katsuhiro Yoshikawa
    Mitsuaki Ishida
    Hirotsugu Yanai
    Koji Tsuta
    Mitsugu Sekimoto
    Tomoharu Sugie
    BMC Cancer, 21
  • [5] Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1-positive Triple-negative Breast Cancer
    Carter, Jodi M.
    Polley, Mei-Yin C.
    Leon-Ferre, Roberto A.
    Sinnwell, Jason
    Thompson, Kevin J.
    Wang, Xue
    Ma, Yaohua
    Zahrieh, David
    Kachergus, Jennifer M.
    Solanki, Malvika
    Boughey, Judy C.
    Liu, Minetta C.
    Ingle, James N.
    Kalari, Krishna R.
    Couch, Fergus J.
    Thompson, E. Aubrey
    Goetz, Matthew P.
    CLINICAL CANCER RESEARCH, 2021, 27 (20) : 5628 - 5637
  • [6] Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions
    Kagihara, Jodi A.
    Andress, Michelle
    Diamond, Jennifer R.
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2020, 5 (02): : 59 - 65
  • [7] KEYNOTE-086 cohort B: Pembrolizumab monotherapy for PD-L1-positive, previously untreated, metastatic triple-negative breast cancer (mTNBC)
    Adams, Sylvia
    Loi, Sherene
    Toppmeyer, Deborah L.
    Cescon, David W.
    De laurentiis, Michele
    Nanda, Rita
    Winer, Eric P.
    Mukai, Hirofumai
    Tamura, Kenji
    Armstrong, Anne C.
    Liu, Minetta C.
    Iwata, Hiroji
    Ryvo, Larisa
    Wimberger, Pauline
    Rugo, Hope S.
    Tan, Antoinette
    D'Aquanno, Christine
    Ding, Yu
    Karantza, Vassiliki
    Schmid, Peter
    CANCER RESEARCH, 2018, 78 (04)
  • [8] Cost-effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer
    Huang, Min
    Fasching, Peter
    Haiderali, Amin
    Pan, Wilbur
    Gray, Emma
    Zhou, Zheng-Yi
    Hu, Peter
    Chaudhuri, Mitashri
    De Tilleghem, Celine Le Bailly
    Cappoen, Nicolas
    O'Shaughnessy, Joyce
    IMMUNOTHERAPY, 2022, 14 (13) : 1027 - 1041
  • [9] Pembrolizumab for PD-L1-Positive Breast Cancer Refractory to Chemotherapy
    Phan, Kim
    Charif, Mahmoud
    AMERICAN JOURNAL OF THERAPEUTICS, 2020, 27 (06) : E622 - E624
  • [10] Finding the positive in triple-negative breast cancer
    Carey, Lisa A.
    NATURE CANCER, 2021, 2 (05) : 476 - 478
12345